Tags

Type your tag names separated by a space and hit enter

HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction.
Am J Transplant. 2005 Jan; 5(1):131-8.AJ

Abstract

Bronchiolitis obliterans syndrome (BOS) represents a major limitation in lung transplantation. While acute rejection is widely considered the most important risk factor for BOS, the impact of HLA-specific antibodies is less understood. Of 51 lung recipients who were prospectively tested during a 4.2 +/- 1.6-year period, 14 patients developed HLA-specific antibodies. A multi-factorial analysis was performed to correlate the prevalence of BOS with HLA antibodies, persistent-recurrent acute rejection (ACR-PR), lymphocytic bronchiolitis, and HLA-A, -B, and -DR mismatches. HLA-specific antibodies were associated with ACR-PR (10/14 vs. 11/37 with no antibodies, p < 0.05), lymphocytic bronchiolitis (8/14 vs. 10/37, p < 0.05), and BOS (10/14, vs. 9/37, p < 0.005). Other risk factors for BOS were: lymphocytic bronchiolitis (13/18 vs. 6/33 with no lymphocytic bronchiolitis, p < 0.0001), ACR-PR (12/21 vs. 7/30 with no ACR-PR, p < 0.05), and the number of HLA-DR mismatches (1.7 +/- 0.48 in BOS vs. 1.2 +/- 0.63 without BOS, p < 0.05). The presence of antibodies exhibited a cumulative effect on BOS when it was associated with either lymphocytic bronchiolitis or ACR-PR. The complex relationship between the development of HLA antibodies and acute and chronic lung allograft rejection determines the importance of post-transplant screening for HLA-specific antibodies as a prognostic element for lung allograft outcome.

Authors+Show Affiliations

Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

15636621

Citation

Girnita, Alin L., et al. "HLA-specific Antibodies Are Risk Factors for Lymphocytic Bronchiolitis and Chronic Lung Allograft Dysfunction." American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 5, no. 1, 2005, pp. 131-8.
Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant. 2005;5(1):131-8.
Girnita, A. L., Duquesnoy, R., Yousem, S. A., Iacono, A. T., Corcoran, T. E., Buzoianu, M., Johnson, B., Spichty, K. J., Dauber, J. H., Burckart, G., Griffith, B. P., McCurry, K. R., & Zeevi, A. (2005). HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 5(1), 131-8.
Girnita AL, et al. HLA-specific Antibodies Are Risk Factors for Lymphocytic Bronchiolitis and Chronic Lung Allograft Dysfunction. Am J Transplant. 2005;5(1):131-8. PubMed PMID: 15636621.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. AU - Girnita,Alin L, AU - Duquesnoy,Rene, AU - Yousem,Samuel A, AU - Iacono,Aldo T, AU - Corcoran,Timothy E, AU - Buzoianu,Manuela, AU - Johnson,Bruce, AU - Spichty,Kathy J, AU - Dauber,James H, AU - Burckart,Gilbert, AU - Griffith,Bartley P, AU - McCurry,Kenneth R, AU - Zeevi,Adriana, PY - 2005/1/8/pubmed PY - 2005/5/25/medline PY - 2005/1/8/entrez SP - 131 EP - 8 JF - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JO - Am. J. Transplant. VL - 5 IS - 1 N2 - Bronchiolitis obliterans syndrome (BOS) represents a major limitation in lung transplantation. While acute rejection is widely considered the most important risk factor for BOS, the impact of HLA-specific antibodies is less understood. Of 51 lung recipients who were prospectively tested during a 4.2 +/- 1.6-year period, 14 patients developed HLA-specific antibodies. A multi-factorial analysis was performed to correlate the prevalence of BOS with HLA antibodies, persistent-recurrent acute rejection (ACR-PR), lymphocytic bronchiolitis, and HLA-A, -B, and -DR mismatches. HLA-specific antibodies were associated with ACR-PR (10/14 vs. 11/37 with no antibodies, p < 0.05), lymphocytic bronchiolitis (8/14 vs. 10/37, p < 0.05), and BOS (10/14, vs. 9/37, p < 0.005). Other risk factors for BOS were: lymphocytic bronchiolitis (13/18 vs. 6/33 with no lymphocytic bronchiolitis, p < 0.0001), ACR-PR (12/21 vs. 7/30 with no ACR-PR, p < 0.05), and the number of HLA-DR mismatches (1.7 +/- 0.48 in BOS vs. 1.2 +/- 0.63 without BOS, p < 0.05). The presence of antibodies exhibited a cumulative effect on BOS when it was associated with either lymphocytic bronchiolitis or ACR-PR. The complex relationship between the development of HLA antibodies and acute and chronic lung allograft rejection determines the importance of post-transplant screening for HLA-specific antibodies as a prognostic element for lung allograft outcome. SN - 1600-6135 UR - https://www.unboundmedicine.com/medline/citation/15636621/HLA_specific_antibodies_are_risk_factors_for_lymphocytic_bronchiolitis_and_chronic_lung_allograft_dysfunction_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1600-6135&amp;date=2005&amp;volume=5&amp;issue=1&amp;spage=131 DB - PRIME DP - Unbound Medicine ER -